3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
36
Carcinoma, Non-Small-Cell Lung
29
Triple Negative Breast Neoplasms
23
Nasopharyngeal Carcinoma
23
Stomach Neoplasms
21
Esophageal Squamous Cell Carcinoma
19
Esophageal Neoplasms
19
Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
14
Colorectal Neoplasms
12
Uterine Cervical Neoplasms
11
Sarcoma
10
Pancreatic Neoplasms
9
Lung Neoplasms
9
Recurrence
7
Neoplasm Metastasis
7
Melanoma
6
Hodgkin Disease
6
Cholangiocarcinoma
6
Liver Neoplasms
5
Biliary Tract Neoplasms
5
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Neoplasms
4
Advanced Solid Tumor
4
Advanced Gastric Cancer
4
Solid Tumor
3
Respiratory Tract Diseases
3
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
pembrolizumab
10
Nivolumab
9
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
sintilimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Turcot syndrome
×
camrelizumab
×
Clear all
NCT06215677
2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA
Recruiting
18 enrolled